Vienna, Austria- January 19 2009- Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, today announced that it has appointed William Prince, Ph.D. M.D. as its Chief Medical Officer.
Dr. Prince joins Nabriva Therapeutics from Surface Logix Inc., where he was Chief Development Officer. At Surface Logix, he not only represented the Company externally in scientific, financial and business development communities, but he also helped to build the Company’s clinical development infrastructure and successfully conducted drug development programs of novel therapeutic agents. During his extensive career in the pharmaceutical industry, Dr. Prince has specialised in early development, clinical pharmacology, discovery and translational science in a number of therapeutic areas. In the field of anti-infectives he has made important contributions to the successful clinical development of several approved and marketed antibiotics and antiviral drugs, and has signed off on numerous regulatory packages.
“Dr. Prince is a highly qualified, experienced pharmaceutical physician with significant anti-infectives development competencies, having worked with antibiotics, anti-fungals and anti-virals for 15 years at GlaxoSmithKline,” said George Golumbeski, CEO of Nabriva Therapeutics. “He brings with him a considerable amount of knowledge and strength in the areas of scientific and commercial development, which is very important as Nabriva continues to further progress and develop its pipeline.”
“I am truly excited to be joining a company with such promising compounds in development,” said Dr. William Prince, the new Chief Medical Officer at Nabriva Therapeutics. “Having worked with antibiotics and anti-virals in the past, I look forward to exploring the development of pleuromutilins as a new class of antibiotics for serious infections.”
Dr. Prince combines a background as a pharmaceutical physician with extensive experience in the development and commercialisation of both pharmaceutical and biotechnology products. He has over 25 years experience in clinical pharmacology and pharmaceutical medicine, leading all phases of drug development from candidate selection through to market support. He received his Ph.D in pharmacology and his medicinal degrees from the University of Cambridge.
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens. The Company’s lead programs are clinical stage pleuromutilin antibiotics, which are available for IV and oral step-down therapy. These antibiotic compounds have substantial medical and market potential since they offer a truly unique antimicrobial profile, excellent potency and have the potential to be safer than currently available antibiotics. Nabriva’s two systemic products, BC-3205 and BC-3781, are orally and IV available and are scheduled to enter, respectively, Phase II and Phase I clinical trials in 2009. The Company also has a Phase I non-systemic pleuromutilin product, BC-7013, for the treatment of gastrointestinal complications caused by the over-proliferation of Clostridium difficile. Nabriva Therapeutics has a proven track record in world class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva Therapeutics is located in Vienna, Austria. For more information on Nabriva please visit www.nabriva.com
